A major competitive advantage can be gained by companies that unlock the value hidden in the vast quantity of healthcare data available today – particularly that presented by real-world data.
Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need, becomes i
Phenestra's latest white paper highlights the challenges in market access and reimbursement for every company involved in developing new and innovative drugs.
The personalised medicine approach is rapidly becoming the new norm for pharmaceutical industry drug development and commercialisation, but it demands much more forward-thinking decision-making